The effect of antiparkinsonian drugs on oxidative stress induced pathological [3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices

Neuropharmacology

Volumn 58, Issue 4-5, 2010, Pages 816-825

  Milusheva, Elisaveta ^a,b   Baranyi, Mária ^a   Kormos, Eszter ^a   Hracskó, Zsuzsanna ^a   Sylvester Vizi, E ^a   Sperlágh, Beáta ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

Author keywords

Antiparkinsonian drugs; Dopamine release; H2O2; Oxidative stress; Rotenone; Striatum

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIPARKINSON AGENT; DOPAMINE; HYDROGEN PEROXIDE; LEVODOPA; RASAGILINE; ROPINIROLE; ROTENONE; SELEGILINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINE UPTAKE; IN VITRO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DOPAMINE; MALE; ORGAN CULTURE TECHNIQUES; OXIDATIVE STRESS; PC12 CELLS; RATS; RATS, WISTAR; ROTENONE;

EID: 77649336945     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.11.017     Document Type: Article

References (45)

1. Atkinson D.E. The energy charge of the adenylate pool as a regulatory parameter: interaction with feedback modifiers. Biochemistry 1968, 7:4030-4034.
2. Azzaro A.J., King J., Kotzuk J., Schoepp D.D., Frost J., Schochet S. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism. J. Neurochem. 1985, 45:949-956.
3. Baranyi M., Milusheva E., Vizi E.S., Sperlagh B. Chromatographic analysis of dopamine metabolism in a Parkinsonian model. J. Chromatogr. A 2006, 1120:13-20.
4. 2 elevation, not ATP depletion. J. Neurosci. 2005, 25:10029-10040.
5. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
6. Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?. CNS Drug Rev. 2005, 11:183-194.
7. Butcher S.P., Fairbrother I.S., Kelly J.S., Arbuthnott G.W. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 1990, 55:981-988.
8. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
9. Dluzen D.E., McDermott J.L. The effect of long-term treatment with deprenyl on basal and l-dopa evoked dopamine release in vitro from the corpus striatum of aged rats. J. Neural Transm. Suppl. 1991, 85:145-156.
10. Dukes A.A., Korwek K.M., Hastings T.G. The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells. Antioxid. Redox Signal. 2005, 7:630-638.
11. Dyck L.E., Yang C.R., Boulton A.A. The biosynthesis of p-tyramine, m-tyramine and beta-phenylethylamine by rat striatal slices. J. Neurosci. Res. 1983, 10:211-220.
12. Eden R.J., Costall B., Domeney A.M., Gerrard P.A., Harvey C.A., Kelly M.E., Naylor R.J., Owen D.A., Wright A. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol. Biochem. Behav. 1991, 3:147-154.
13. Fahn S., Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1:139-154.
14. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508.
15. Finberg J.P., Lamensdorf I., Commissiong J.W., Youdim M.B. Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. Suppl. 1996, 48:95-101.
16. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 1978, 14:633-643.
17. Green A.R., Mitchell B.D., Tordoff A.F., Youdim M.B. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 1977, 60:343-349.
18. Jin S., Johansson B., Fredholm B.B. Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J. Pharmacol. Exp. Ther. 1993, 267:801-808.
19. Juranyi Z., Sziray N., Marko B., Levay G., Harsing L.G. AMPA receptor blockade potentiates the stimulatory effect of l-DOPA on dopamine release in dopamine-deficient corticostriatal slice preparation. Crit. Rev. Neurobiol. 2004, 16:129-139.
20. Lamensdorf I., Youdim M.B., Finberg J.P. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem. 1996, 67:1532-1539.
21. Lamensdorf I., Porat S., Simantov R., Finberg J.P. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br. J. Pharmacol. 1999, 126:997-1002.
22. Limberger N., Trout S.J., Kruk Z.L., Starke K. "Real time" measurement of endogenous dopamine release during short trains of pulses in slices of rat neostriatum and nucleus accumbens: role of autoinhibition. Naunyn Schmiedebergs Arch. Pharmacol. 1991, 344:623-629.
23. Lloyd K.G., Davidson L., Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of l-dopa therapy. J. Pharmacol. Exp. Ther. 1975, 195:453-464.
24. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
25. Martone R.M.M., Pangalos M. Parkinson's disease as a disorder of the aging. Drug Discov. Today Therapeutic Strategies 2005, 2:299-305.
26. Milusheva E., Baranyi M., Kittel A., Fekete A., Zelles T., Vizi E.S., Sperlágh B. Modulation of dopaminergic neurotransmission in rat striatum upon in vitro and in vivo diclofenac treatment. J. Neurochem. 2008, 105:360-368.
27. Milusheva E., Baranyi M., Kittel A., Sperlagh B., Vizi E.S. Increased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment. Free Radic. Biol. Med. 2005, 39:133-142.
28. 3H]noradrenaline in response to oxidative stress combined with mitochondrial dysfunction in rat hippocampal slices. Neuroscience 2003, 120:771-781.
29. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur. Neurol. 1994, 34(Suppl 3):20-28.
30. Ogawa N., Tanaka K., Asanuma M. Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum. Neurochem. Res. 2000, 25:755-758.
31. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., De Yebenes J.G. Toxic effects of l-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 1995, 682:133-143.
32. Ren Y., Liu W., Jiang H., Jiang Q., Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 2005, 280:34105-34112.
33. Sai Y., Wu Q., Le W., Ye F., Li Y., Dong Z. Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism. Toxicol. in Vitro 2008, 22:1461-1468.
34. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
35. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 2003, 179:9-16.
36. Snyder G.L., Keller R.W., Zigmond M.J. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J. Pharmacol. Exp. Ther. 1990, 253:867-876.
37. Sulzer D., Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res. 2000, 1:181-195.
38. Vizi E.S. Different temperature dependence of carrier-mediated (cytoplasmic) and stimulus-evoked (exocytotic) release of transmitter: a simple method to separate the two types of release. Neurochem. Int. 1998, 33:359-366.
39. Vizi E.S. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol. Rev. 2000, 52:63-89.
40. Walkinshaw G., Waters C.M. Induction of apoptosis in catecholaminergic PC12 cells by l-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 1995, 95:2458-2464.
41. Wang G., Zeng J., Shen C.Y., Wang Z.Q., Chen S.D. Overexpression of Kir2.3 in PC12 cells resists rotenone-induced neurotoxicity associated with PKC signaling pathway. Biochem. Biophys. Res. Commun. 2008, 374:204-209.
42. Whitehead R.E., Ferrer J.V., Javitch J.A., Justice J.B. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem. 2001, 76:1242-1251.
43. Yang H.Y., Neff N.H. The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J. Pharmacol. Exp. Ther. 1974, 189:733-740.
44. Youdim M.B., Riederer P.F. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 2004, 63:S32-35.
45. Zsilla G., Foldi P., Held G., Szekely A.M., Knoll J. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol. J. Pharmacol. Pharm. 1986, 38:57-67.